Syed Ahmed

Stent For Increasing Blood Flow To Ischemic Tissues And A Method Of Using The Same

Application

#6660034 Dec 9, 2003

Filed

Apr 30, 2001

Inventor

Evgenia Mandrusov (Campbell, CA) · Paul Consigny (Morgan Hill, CA) · Syed Faiyaz Ahmed Hossainy (Fremont, CA) · Dary Mirzaee (Sunnyvale, CA)

Appl. No.

09/846498

Assignee

Advanced Cardiovascular Systems, Inc. (Santa Clara, CA)

International Classification

A61F 206

U.S. Classification

623 142

Abstract

An implantable stent for a vessel includes a tubular body having an inner and outer surface. The inner and outer surfaces are coated with therapeutic substances. The therapeutic substance of the inner surface, such as an angiogenic substance, can be released downstream in the lumen. The therapeutic substance of the outer surface can be applied to the inner surface of the vessel.

Claim

What is claimed is: 1. A stent, comprising: a tubular body having an outer surface configured to contact the wall of a vessel and an inner surface; a first coating supported by the inner surface and containing an angiogenic substance, the first coating configured to release the angiogenic substance in the vessel; and a second coating supported by the outer surface and containing a therapeutic substance capable of inhibiting migration or proliferation of smooth muscle cells, the second coating configured to apply the therapeutic substance to the wall of the vessel, wherein the outer surface is free from the first coating containing the angiogenic substance and the inner surface is free from the second coating containing the therapeutic substance. 2. The stent of claim 1, wherein the angiogenic substance is selected from a group of vascular endothelial growth factor, fibroblast growth factors, monocyte chemoattractant protein 1, transforming growth factor beta, transforming growth factor alpha, lipid factors, hypoxia-inducible factor 1-alpha, PR39, del 1, nicotine, insulin-like growth factors, placental growth factor, hepatocyte growth factor, estrogen, follistatin, proliferin, cytokines, tumor necrosis factor, erythropoietin, granulocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor, angiogenin, hormones, and genes that encode such substances. 3. The stent of claim 1, wherein the angiogenic substance is a vascular endothelial growth factor. 4.

Method For Extending Shelf-Life Of Constructs Of Semi-Crystallizable Polymers

Application

#7297758 Nov 20, 2007

Filed

Aug 2, 2005

Inventor

David C. Gale (San Jos, CA) · Syed Faiyaz Ahmed Hossainy (Fremont, CA) · Bin Huang (Shoreview, MN) · Klaus Kleine (Los Gatos, CA)

Appl. No.

11/195974

Assignee

Advanced Cardiovascular Systems, Inc. (Santa Clara, CA)

International Classification

C08F 6/00

U.S. Classification

528480, 2641761, 264219, 424422, 424426, 528481, 606108, 623 115

Abstract

This invention relates to a method of extending the shelf-life of constructs, in particular bioabsorbable stents, comprising semi-crystalline polymers by increasing the crystallinity of the polymers.

Heparin Prodrugs And Drug Delivery Stents Formed Therefrom

Application

#7563780 Jul 21, 2009

Filed

Jun 18, 2004

Inventor

Syed Faiyaz Ahmed Hossainy (Fremont, CA) · Ni Ding (San Jose, CA)

Appl. No.

10/871658

Assignee

Advanced Cardiovascular Systems, Inc. (Santa Clara, CA)

International Classification

C08B 37/10, A61K 31/727, A61P 7/02

U.S. Classification

514 56, 536 21

Abstract

A prodrug comprising a heparin and a drug is provided. The prodrug can be used to form a coating on a medical device. The prodrug can also be used with a polymeric material to form a coating on a medical device. The polymeric material can be a hydrophobic polymer, a hydrophilic polymer, a non-fouling polymer, or combinations thereof. The medical device can be implanted in a human being for the treatment of a disease such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, or combinations thereof.

Method Of Manufacturing A Stent Coating And A Method Of Using The Stent

Application

#7625593 Dec 1, 2009

Filed

Oct 2, 2003

Inventor

Evgenia Mandrusov (Campbell, CA) · Paul Consigny (Morgan Hill, CA) · Syed Faiyaz Ahmed Hossainy (Fremont, CA) · Dary Mirzaee (Sunnyvale, CA)

Appl. No.

10/678763

Assignee

Advanced Cardiovascular Systems, Inc. (Santa Clara, CA)

International Classification

B05D 5/00

U.S. Classification

427 224, 427 225

Abstract

A method of manufacturing a drug-eluting coating for a stent is disclosed. A method for increasing blood flow to ischemic tissues by implanting the stent is also disclosed.

Controlled Degradation Of Stents

Application

#7794495 Sep 14, 2010

Filed

Jul 17, 2006

Inventor

David C. Gale (San Jose, CA) · Bin Huang (Pleasanton, CA) · Vincent J. Gueriguian (San Francisco, CA) · Syed Faiyaz Ahmed Hossainy (Fremont, CA)

Appl. No.

11/488928

Assignee

Advanced Cardiovascular Systems, Inc. (Santa Clara, CA)

International Classification

A61F 2/06, C08G 63/08

U.S. Classification

623 149, 528354

Abstract

Stents fabricated from hydrolytically degradable polymers with accelerated degradation rates and methods of fabricating stents with accelerated degradation rates are disclosed.

System, Method And Computer-Readable Medium For Detection And Avoidance (Daa) Of Victim Services In Ultra-Wideband Systems (Uwb)

Application

#7869529 Jan 11, 2011

Filed

Jun 13, 2007

Inventor

Sridhar Rajagopal (Plano, TX) · Brian C. Joseph (McKinney, TX) · Syed N. Ahmed (Allen, TX) · Yaming Zhang (Plano, TX)

Appl. No.

11/762659

Assignee

QUALCOMM Incorporated (San Diego, CA)

International Classification

H04K 1/10

U.S. Classification

375260

Abstract

A system for detection and avoidance of victim services in ultra-wideband (UWB) systems is provided. A detect and avoid module may calculate power averages of Orthogonal Frequency Division Multiplexing tones. The power of tones may be measured and compared with power averages of corresponding tones. If a measured tone power exceeds an average power of a corresponding tone by a dynamic threshold, the tone may be identified as associated with an interferer. The threshold may be inversely related to the gain level of an automatic gain control module. The UWB subsystem may be configured with known bands of victim services of other radio frequency systems, and a tone identified as associated with an interferer that is within a known victim service band may be identified as a victim service. The UWB subsystem may attenuate or otherwise suppress transmission within the victim service band to avoid interfering with the victim service.